


Gastric cancer: Preclinical models to identify and characterize clinically relevant therapeutic targets



Dr Lau Wen Min

Associate Staff Scientist
Expression Engineering 1, BTI

**22 February 2019, Friday
2.00pm**

**BTI Boardroom
Level 6, Centros**

Hosted by Dr Song Zhiwei

Seminar Abstract

Gastric cancer is a heterogeneous disease, and remains a difficult malignancy to treat. Gastric tumors exhibit different patterns of molecular aberrations, disease aggressiveness and treatment response, underlining the need for more targeted treatments. However, targeted therapy options for gastric cancer are few, partly due to a lack of known effective molecular targets. This presentation will describe the use of patient-derived gastric cancer xenografts as a platform for identification and functional characterization of novel therapeutic targets, as well as for preclinical evaluation of drug efficacy and response.

About the Speaker

Wen Min received her BBiotech(Hons) degree from Flinders University in South Australia, and her PhD from the Department of Biochemistry at the National University of Singapore, during which she studied the oncogenesis of cervical cancer. During her postdoctoral fellowship in the Department of Orthopaedic Surgery at Johns Hopkins University School of Medicine, she worked on elucidating factors which mediate breast cancer bone metastasis. She then joined the Cancer Science Institute of Singapore where she established patient-derived xenograft models of gastric cancer in order to identify and develop clinically relevant therapeutic targets for preclinical evaluation and drug efficacy studies.